Antibodies that cross-react with multiple HIV-1 envelopes (Envs) are useful reagents for characterizing Env proteins and for soluble Env capture and purification assays. We previously reported 10 murine monoclonal antibodies induced by group M consensus Env, CON-6 immunization. Each demonstrated broad cross-reactivity to recombinant Envs. Here we characterized the Env epitopes to which they bind. Seven mapped to linear epitopes in gp120, five at the Env N-terminus, and two at the Env C-terminus. One antibody, 13D7, bound at the gp120 N-terminus (aa 30–42), reacted with HIV-1-infected CD4+ T cells, and when expressed in a human IgG1 backbone, mediated antibody-dependent cellular cytotoxicity. Antibody 18F11 bound at the gp120 C-terminus (aa 445–459) and reactivity was glycan dependent. Antibodies 13D7, 3B3, and 16H3 bound to 100 percent of HIV-1 Envs tested in ELISA and sodium dodecyl sulfate/polyacrylamide gel electrophoresis/western blot analysis. These data define the epitopes of monoclonal antibody reagents for characterization of recombinant Envs, one epitope of which is also expressed on the surface of HIV-1-infected CD4+ T cells.
Get full access to this article
View all access options for this article.
References
1.
BradleyT, FeraD, BhimanJ, et al.: Structural constraints of vaccine-induced tier-2 autologous HIV neutralizing antibodies targeting the receptor-binding site. Cell Rep, 2016; 14:43–54.
2.
HaynesBF, GilbertPB, McElrathMJ, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 2012; 366:1275–1286.
3.
HaynesBF, KelsoeG, HarrisonSC, KeplerTB: B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol, 2012; 30:423–433.
4.
HuJK, CramptonJC, CupoA, et al.: Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity. J Virol, 2015; 89:10383–10398.
5.
JardineJ, JulienJP, MenisS, et al.: Rational HIV immunogen design to target specific germline B cell receptors. Science, 2013; 340:711–716.
6.
KangYK, AndjelicS, BinleyJM, et al.: Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine, 2009; 27:5120–5132.
7.
Rerks-NgarmS, PitisuttithumP, NitayaphanS, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361:2209–2220.
8.
WilliamsWB, LiaoHX, MoodyMA, et al.: HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015; 349:aab1253.
9.
BonsignoriM, HwangKK, ChenX, et al.: Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol, 2011; 85:9998–10009.
10.
BonsignoriM, WieheK, GrimmSK, et al.: An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest, 2014; 124:1835–1843.
11.
BonsignoriM, ZhouT, ShengZ, et al.: Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-Mimic antibody. Cell, 2016; 165:449–463.
12.
CalareseDA, ScanlanCN, ZwickMB, et al.: Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science, 2003; 300:2065–2071.
13.
Doria-RoseNA, BhimanJN, RoarkRS, et al.: New member of the V1V2-Directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J Virol, 2015; 90:76–91.
14.
GarcesF, LeeJH, de ValN, et al.: Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity, 2015; 43:1053–1063.
15.
LiaoHX, LynchR, ZhouT, et al.: Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013; 496:469–476.
16.
PejchalR, DooresKJ, WalkerLM, et al.: A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science, 2011; 334:1097–1103.
17.
ScharfL, ScheidJF, LeeJH, et al.: Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep, 2014; 7:785–795.
18.
SokD, van GilsMJ, PauthnerM, et al.: Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A, 2014; 111:17624–17629.
19.
WalkerLM, HuberM, DooresKJ, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 2011; 477:466–470.
20.
WalkerLM, PhogatSK, Chan-HuiPY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009; 326:285–289.
21.
ZhuJ, O'DellS, OfekG, et al.: Somatic populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatics. Front Microbiol, 2012; 3:315.
22.
ZhuZ, QinHR, ChenW, et al.: Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol, 2011; 85:11401–11408.
23.
YangX, LipchinaI, CocklinS, ChaikenI, SodroskiJ: Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J Virol, 2006; 80:11404–11408.
24.
LiuP, WilliamsLD, ShenX, et al.: Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. J Virol, 2014; 88:5165–5170.
25.
BonsignoriM, PollaraJ, MoodyMA, et al.: Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol, 2012; 86:11521–11532.
26.
FerrariG, PollaraJ, KozinkD, et al.: An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol, 2011; 85:7029–7036.
27.
PollaraJ, BonsignoriM, MoodyMA, PazgierM, HaynesBF, FerrariG: Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res, 2013; 11:378–387.
28.
GaoF, ScearceRM, AlamSM, et al.: Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology, 2009; 394:91–98.
29.
MaBJ, AlamSM, GoEP, et al.: Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog, 2011; 7:e1002200.
30.
PalkerTJ, ScearceRM, MillerSE, et al.: Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. J Exp Med, 1984; 159:1117–1131.
31.
MoodyMA, YatesNL, AmosJD, et al.: HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol, 2012; 86:7496–7507.
32.
KuraokaM, SchmidtAG, NojimaT, et al.: Complex antigens drive permissive clonal selection in germinal centers. Immunity, 2016; 44:542–552.
33.
RohatgiS, GanjuP, SehgalD. Systematic design and testing of nested (RT-)PCR primers for specific amplification of mouse rearranged/expressed immunoglobulin variable region genes from small number of B cells. J Immunol Methods. Dec312008; 339:205–219.
34.
TillerT, BusseCE, WardemannH. Cloning and expression of murine Ig genes from single B cells. J Immunol Methods. Oct312009; 350:183–193.
35.
EdmondsTG, DingH, YuanX, et al.: Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology. Dec052010; 408:1–13.
36.
MontefioriDC: Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol, 2005;Chapter 12:Unit 12.11.
37.
CrooksGE, HonG, ChandoniaJM, BrennerSE. WebLogo: a sequence logo generator. Genome Res. Jun2004; 14:1188–1190.
38.
PanceraM, MajeedS, BanYE, et al.: Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A, 2010; 107:1166–1171.
39.
JulienJP, CupoA, SokD, et al.: Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science, 2013; 342:1477–1483.
40.
KorberB, GaschenB, YusimK, ThakallapallyR, KesmirC, DetoursV: Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull, 2001; 58:19–42.
41.
WeiX, DeckerJM, WangS, et al.: Antibody neutralization and escape by HIV-1. Nature, 2003; 422:307–312.
42.
DooresKJ, BurtonDR: Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol, 2010; 84:10510–10521.
43.
Doria-RoseNA, SchrammCA, GormanJ, et al.: Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014; 509:55–62.
44.
GarcesF, SokD, KongL, et al.: Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell, 2014; 159:69–79.
45.
ScanlanCN, PantophletR, WormaldMR, et al.: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1—>2 mannose residues on the outer face of gp120. J Virol, 2002; 76:7306–7321.
46.
SokD, DooresKJ, BrineyB, et al.: Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med, 2014; 6:236ra263.
47.
BehrensAJ, VasiljevicS, PritchardLK, et al.: Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Rep, 2016; 14:2695–2706.
48.
LiaoHX, ChenX, MunshawS, et al.: Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med, 2011; 208:2237–2249.
49.
HaynesBF, MoodyMA, VerkoczyL, KelsoeG, AlamSM: Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Hum Antibodies, 2005; 14:59–67.
50.
ScheidJF, MouquetH, FeldhahnN, et al.: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 2009; 458:636–640.
51.
TramaAM, MoodyMA, AlamSM, et al.: HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe, 2014; 16:215–226.
52.
ScanlanCN, RitchieGE, BaruahK, et al.: Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol, 2007; 372:16–22.
53.
KongL, Torrents de la PenaA, DellerMC, et al.: Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta Crystallogr D Biol Crystallogr, 2015; 71(Pt 10):2099–2108.
54.
SandersRW, van GilsMJ, DerkingR, et al.: HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 2015; 349:aac4223.
55.
TomarasGD, FerrariG, ShenX, et al.: Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A, 2013; 110:9019–9024.
56.
AcharyaP, TolbertWD, GohainN, et al.: Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol, 2014; 88:12895–12906.
57.
GuanY, PazgierM, SajadiMM, et al.: Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A, 2013; 110:E69–E78.
58.
MooreJP, McCutchanFE, PoonSW, et al.: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol, 1994; 68:8350–8364.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
